Silo pharma announces important milestone. investigator led study using psilocybin to treat parkinson's disease has been submitted for ethics board review.

Englewood cliffs, nj, may 13, 2021 (globe newswire) -- silo pharma, inc. (otcqb: silo) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its  investigator led study using psilocybin to treat parkinson's disease has been submitted for ethics board review  in the netherlands.   eric weisblum, ceo of silo pharma stated “we are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders.”
SILO Ratings Summary
SILO Quant Ranking